AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19385450 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 48
Study 15007784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg/d, with initial run-in of 150 mg/d for the first three days)
Number of subjects: 321
Study 11727145 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 mg/kg
Number of subjects: 30
Study 11727145 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 8976225 — intervention group
Group type: EXPERIMENTAL
Intervention: Filiform dilation
Number of subjects: 210
Study 8976225 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical internal urethrotomy
Number of subjects: 210
Study 8387697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy with fast neutrons (average dose 569 cGy) and photons (average dose 36.86 Gy)
Number of subjects: 39
Study 8387697 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost therapy or mixed beam therapy with localized fast neutron field
Number of subjects: 39
Study 8387697 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 39
Study 3308650 — intervention group
Group type: EXPERIMENTAL
Intervention: TDB 120 mg quid
Number of subjects: 52
Study 3308650 — intervention group
Group type: COMPARATOR
Intervention: cimetidine 400 mg tid
Number of subjects: 52
Study 3308650 — intervention group
Group type: COMPARATOR
Intervention: cimetidine 400 mg with meals plus 800 mg at bedtime
Number of subjects: 52
Study 30612569 — intervention group
Group type: EXPERIMENTAL
Intervention: BiodentineTM pulpotomy
Number of subjects: 37
Study 30612569 — intervention group
Group type: COMPARATOR
Intervention: formocresol pulpotomy
Number of subjects: 37
Study 29061008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral axillary brachial plexus block
Number of subjects: 120
Study 29061008 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulator-guided bilateral axillary brachial plexus block
Number of subjects: 120
Study 25776457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12444
Study 25776457 — intervention group
Group type: COMPARATOR
Intervention: GP IIb/IIIa receptor inhibitors
Number of subjects: 12444
Study 25498776 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics intervention strategies
Number of subjects: 0
Study 25498776 — intervention group
Group type: COMPARATOR
Intervention: Standard economic choice theory
Number of subjects: 0
Study 23264241 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 85
Study 23264241 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2
Number of subjects: 85
Study 23264241 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin
Number of subjects: 85
Study 23264241 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 85
Study 23264241 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 85
Study 23264241 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model
Number of subjects: 85
Study 19827696 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive coping strategies
Number of subjects: 51
Study 19827696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental disengagement
Number of subjects: 51
Study 19827696 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral disengagement
Number of subjects: 51
Study 18159027 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgecine
Number of subjects: 44
Study 18159027 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin tablet
Number of subjects: 44
Study 16335913 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg) and dienogest (2 mg)
Number of subjects: 34
Study 11923458 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically inappropriate sentence-ending words
Number of subjects: 0
Study 11923458 — intervention group
Group type: EXPERIMENTAL
Intervention: N100m response
Number of subjects: 0
Study 11923458 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory N400m response
Number of subjects: 0
Study 9797910 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (1 g calcium carbonate and 14 micrograms vitamin D3)
Number of subjects: 240
Study 9797910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9797910 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 240
Study 8586825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (altizide and spironolactone)
Number of subjects: 653
Study 8586825 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (bisoprolol)
Number of subjects: 653
Study 8586825 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (verapamil)
Number of subjects: 653
Study 8586825 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (enalapril)
Number of subjects: 653
Study 2473400 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis and food hypersensitivity
Number of subjects: 63
Study 2473400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary elimination of offending food allergens
Number of subjects: 63
Study 2473400 — intervention group
Group type: COMPARATOR
Intervention: Atopic dermatitis without food hypersensitivity
Number of subjects: 63
Study 2473400 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 63
Study 1116382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol (0.5 mg)
Number of subjects: 0
Study 1116382 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.2 mg)
Number of subjects: 0
Study 31373886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-aided identification technique (FIT)
Number of subjects: 64
Study 31373886 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (contra-angle handpiece)
Number of subjects: 64
Study 30552786 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention based on the theory of planned behaviour (TPB)
Number of subjects: 382
Study 30552786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study 30552786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 382
Study 29262813 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg (ARB)
Number of subjects: 33
Study 29262813 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB + Hydrochlorothiazide 25 mg (HCT)
Number of subjects: 33
Study 29262813 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition (Lisinopril 40 mg/day)
Number of subjects: 33
Study 29262813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RAASi (Lisinopril 40 mg/day + Valsartan 320 mg/day)
Number of subjects: 33
Study 24795092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doripenem (DRPM) 0.5 g three times daily
Number of subjects: 127
Study 24795092 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS) 0.5 g three times daily
Number of subjects: 127
Study 24795092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doripenem (DRPM)
Number of subjects: 127
Study 24795092 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS)
Number of subjects: 127
Study 23636255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise (treadmill training sessions three times/week for 8 weeks)
Number of subjects: 4
Study 23636255 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 4
Study 23636255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise (treadmill training)
Number of subjects: 4
Study 22262708 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of exercise on a stationary cycle at moderate to vigorous intensity
Number of subjects: 42
Study 22262708 — intervention group
Group type: COMPARATOR
Intervention: Control group reading for the same length of time
Number of subjects: 42
Study 19615907 — intervention group
Group type: EXPERIMENTAL
Intervention: Returning gastric residual volume (GRV)
Number of subjects: 125
Study 19615907 — intervention group
Group type: COMPARATOR
Intervention: Discarding gastric residual volume (GRV)
Number of subjects: 125
Study 16924014 — intervention group
Group type: EXPERIMENTAL
Intervention: Central auditory tests (including pure-tone audiometry, tympanometry, dichotic digits, duration pattern, frequency pattern, gaps in noise tests)
Number of subjects: 8
Study 16924014 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in noise test
Number of subjects: 8
Study 16924014 — intervention group
Group type: COMPARATOR
Intervention: Cognitive impairment assessment
Number of subjects: 8
Study 15008344 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 106
Study 15008344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 106
Study 11535336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 6 month vaccination schedule
Number of subjects: 240
Study 11535336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 12 month vaccination schedule
Number of subjects: 240
Study 11535336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined response (both schedules)
Number of subjects: 240
Study 11535336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccination schedules
Number of subjects: 240
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Brainstem auditory evoked response (BAER) abnormalities in tuberculous meningitis
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Combination of prolonged latency and prolonged interval
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Unilateral and bilateral absent response
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Prolonged latency
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Seizure activities, modified Glasgow coma scale (GCS), raised intracranial pressure (ICP), and TBM stage III
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Age, sex, duration of illness, depressed sensorium, neurological deficit, and CSF findings
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Follow up BAER
Number of subjects: 50
Study 10771863 — intervention group
Group type: COMPARATOR
Intervention: Initial and follow up BAER
Number of subjects: 50
Study 8183472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 0
Study 8183472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3328685 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 40
Study 30958322 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 10
Study 28571996 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (TNF-alpha inhibitor)
Number of subjects: 0
Study 28571996 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study 27318340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia continuous blood purification (HT group)
Number of subjects: 95
Study 27318340 — intervention group
Group type: COMPARATOR
Intervention: Normothermic continuous blood purification (NT group)
Number of subjects: 95
Study 22383331 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 0
Study 22064591 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan in HFPEF trial (I‐PRESERVE)
Number of subjects: 4128
Study 18636266 — intervention group
Group type: EXPERIMENTAL
Intervention: Densiron-68 heavy silicone oil
Number of subjects: 79
Study 16959828 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proteinuria
Number of subjects: 1094
Study 16959828 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR <40 ml/min
Number of subjects: 1094
Study 16959828 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine, urea nitrogen, phosphorus
Number of subjects: 1094
Study 15488354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronised 17 beta‐oestradiol/5 mg dydrogesterone (E/D)
Number of subjects: 362
Study 15488354 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine oestrogens/5 mg medroxyprogesterone acetate (CEE/MPA)
Number of subjects: 362
Study 11514040 — intervention group
Group type: EXPERIMENTAL
Intervention: New uniform power method for sample size calculation in historical control studies
Number of subjects: 0
Study 11514040 — intervention group
Group type: COMPARATOR
Intervention: Randomized design formula
Number of subjects: 0
Study 11514040 — intervention group
Group type: COMPARATOR
Intervention: Makuch and Simon's method
Number of subjects: 0
Study 11514040 — intervention group
Group type: COMPARATOR
Intervention: Historical control design
Number of subjects: 0
Study 9718870 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD/OPP
Number of subjects: 218
Study 9718870 — intervention group
Group type: COMPARATOR
Intervention: ABVD/MOPP
Number of subjects: 218
Study 7826792 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, self-administered using PCA, mean 275 micrograms)
Number of subjects: 30
Study 7826792 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, administered by a nurse on request, mean 144 micrograms)
Number of subjects: 30
Study 7826792 — intervention group
Group type: COMPARATOR
Intervention: i.m. morphine (mean 52 mg, range 30‐80 mg, administered on request)
Number of subjects: 30
Study 3041935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled intermittent coronary sinus occlusion (PICSO) for one hour during early reperfusion
Number of subjects: 30
Study 3041935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PICSO)
Number of subjects: 30
Study 3041935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled intermittent coronary sinus occlusion (PICSO)
Number of subjects: 30
Study 31130722 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-gene recurrence score (RS) assay (EndoPredict®)
Number of subjects: 0
Study 31130722 — intervention group
Group type: EXPERIMENTAL
Intervention: 58-gene RS assay (Prosigna®)
Number of subjects: 0
Study 31130722 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene RS assay (Oncotype DX®)
Number of subjects: 0
Study 31219715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (strengths-focused HIV prevention program)
Number of subjects: 860
Study 31219715 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control program)
Number of subjects: 860
Study 28754119 — intervention group
Group type: EXPERIMENTAL
Intervention: YY-312 (2400 mg daily, containing 1800 mg of active herbal extract and 600 mg of cyclodextrin)
Number of subjects: 0
Study 28754119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26618455 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (hyaluronic acid gel)
Number of subjects: 167
Study 23110613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 144
Study 23110613 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 144
Study 20863604 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural childbirth preparation with psychoprophylaxis
Number of subjects: 2151
Study 20863604 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal education
Number of subjects: 2151
Study 19485825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg with caffeine 30 mg
Number of subjects: 15
Study 19485825 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 15
Study 17243592 — intervention group
Group type: EXPERIMENTAL
Intervention: ViscoStat (VS)
Number of subjects: 60
Study 17243592 — intervention group
Group type: EXPERIMENTAL
Intervention: ViscoStat Plus (VS+)
Number of subjects: 60
Study 17243592 — intervention group
Group type: EXPERIMENTAL
Intervention: ViscoStat and blood (VS/B)
Number of subjects: 60
Study 17243592 — intervention group
Group type: EXPERIMENTAL
Intervention: ViscoStat Plus and blood (VS+/B)
Number of subjects: 60
Study 17243592 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study 14686080 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment package targeting headache symptoms and associated posttraumatic stress symptoms
Number of subjects: 14
Study 14686080 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (Control)
Number of subjects: 14
Study 14686080 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment package
Number of subjects: 14
Study 12549975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (2 g)
Number of subjects: 100
Study 12549975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C (4 g/day for 4 weeks)
Number of subjects: 100
Study 12549975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11024416 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beta-blockers
Number of subjects: 1636
Study 11024416 — intervention group
Group type: COMPARATOR
Intervention: Close observation (no topical medication)
Number of subjects: 1636
Study 8851288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI)
Number of subjects: 110
Study 8851288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 1729317 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC) or Streptokinase
Number of subjects: 359
Study 1729317 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 perfusion
Number of subjects: 359
Study 6362832 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with nonviable Mycobacterium smegmatis, given monthly by subcutaneous injection in four sites.
Number of subjects: 219
Study 6362832 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment).
Number of subjects: 219
Study 3543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 to 360 mg)
Number of subjects: 15
Study 3543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg)
Number of subjects: 15
Study 3543092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and nifedipine
Number of subjects: 15
Study 3543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 3543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 15
Study 31811562 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis therapy (twice per month for 12 months)
Number of subjects: 164
Study 31811562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no apheresis treatment)
Number of subjects: 164
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sexual activity (yes/no)
Number of subjects: 1255
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile function measured by the 5-item International Index of Erectile Function (IIEF-5)
Number of subjects: 1255
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 1255
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 1255
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) in sexually active participants
Number of subjects: 1255
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) in sexually active participants
Number of subjects: 1255
Study 30655182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) in sexually active participants
Number of subjects: 1255
Study 28901538 — intervention group
Group type: EXPERIMENTAL
Intervention: Rested state
Number of subjects: 19
Study 28901538 — intervention group
Group type: COMPARATOR
Intervention: Fatigued state
Number of subjects: 19
Study 28901538 — intervention group
Group type: COMPARATOR
Intervention: Self-ratings of clinical performance
Number of subjects: 19
Study 26126079 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth services in home healthcare agencies
Number of subjects: 1582
Study 26126079 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth services in assisted living facilities
Number of subjects: 1582
Study 26126079 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1582
Study 23249916 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infant nevirapine (NVP) administration
Number of subjects: 38
Study 23249916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23249916 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral treatment regimen (including NVP or efavirenz)
Number of subjects: 38
Study 23249916 — intervention group
Group type: COMPARATOR
Intervention: No maternal antiretroviral treatment
Number of subjects: 38
Study 21778674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid training method (HYB)
Number of subjects: 30
Study 21778674 — intervention group
Group type: COMPARATOR
Intervention: Isometric electrical stimulation (ES)
Number of subjects: 30
Study 21778674 — intervention group
Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 30
Study 21778674 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HYB, ES, CN)
Number of subjects: 30
Study 19564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum)
Number of subjects: 103
Study 19564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum)
Number of subjects: 103
Study 19564304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 19564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (before treatment)
Number of subjects: 103